Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $209000.0.

  • Utah Medical Products' Depreciation and Depletion rose 295.57% to $209000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $814000.0, marking a year-over-year increase of 1831.4%. This contributed to the annual value of $730000.0 for FY2024, which is 1717.5% up from last year.
  • Utah Medical Products' Depreciation and Depletion amounted to $209000.0 in Q3 2025, which was up 295.57% from $205000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Depreciation and Depletion registered a high of $209000.0 during Q3 2025, and its lowest value of $149000.0 during Q1 2022.
  • Over the past 5 years, Utah Medical Products' median Depreciation and Depletion value was $158000.0 (recorded in 2021), while the average stood at $169210.5.
  • Per our database at Business Quant, Utah Medical Products' Depreciation and Depletion plummeted by 858.9% in 2022 and then skyrocketed by 3096.77% in 2024.
  • Over the past 5 years, Utah Medical Products' Depreciation and Depletion (Quarter) stood at $153000.0 in 2021, then rose by 3.27% to $158000.0 in 2022, then changed by 0.0% to $158000.0 in 2023, then rose by 26.58% to $200000.0 in 2024, then grew by 4.5% to $209000.0 in 2025.
  • Its Depreciation and Depletion was $209000.0 in Q3 2025, compared to $205000.0 in Q2 2025 and $200000.0 in Q1 2025.